高危出血风险患者肾活检前使用去氨加压素
本研究为回顾性队列研究,纳入2013年4月至2018年4月在一家三级医院接受原生肾活检的413例成人患者,79%使用了去氨加压素。使用去氨加压素者肾功能更差(eGFR 28 vs 45 ml/min per 1.73 m2,P < 0.001)且住院比例更高(48% vs 32%,P = 0.009),但症状性血肿风险相似(OR 0.39,95%CI 0.13-1.14),紧急影像学检查需求更低(OR 0.33,95%CI 0.11-0.98)。
要点
- 高危出血患者肾活检前使用去氨加压素,症状性血肿风险与未使用者相似。
- 使用去氨加压素者紧急影像学检查需求更低(OR 0.33,95%CI 0.11-0.98)。
- 使用去氨加压素者基线肾功能更差且住院比例更高,提示出血风险更高。
核心结论
- 高危出血风险患者肾活检前使用去氨加压素,出血并发症与未使用者相似,且紧急影像学检查需求更低。
研究设计与样本
- 回顾性队列研究,纳入2013年4月1日至2018年4月30日在一家三级医院接受原生肾活检的所有成人患者,共413例活检。
主要发现
- 79%的活检在去氨加压素使用后进行。
- 使用去氨加压素者eGFR更低(28 vs 45 ml/min per 1.73 m2,P < 0.001),住院比例更高(48% vs 32%,P = 0.009)。
- 症状性血肿的OR为0.39(95%CI 0.13-1.14),紧急影像学检查的OR为0.33(95%CI 0.11-0.98)。
临床怎么用
- 对于出血高危患者,肾活检前可考虑使用去氨加压素以降低紧急影像学检查需求。
局限性
- 回顾性设计,可能存在选择偏倚;仅一家三级医院数据,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To prevent bleeding after native kidney biopsy (NKB), nephrologists often prescribe desmopressin, especially for patients with reduced estimated glomerular filtration rate (eGFR) at risk of uremia-related platelet dysfunction. However, only 1 randomized study has suggested a beneficial effect for desmopressin in patients with eGFR ≥60 ml/min per 1.73 m2. This retrospective cohort study aimed to evaluate desmopressin effect on postbiopsy bleeding in all patients, regardless of eGFR and other comorbidities. METHODS: In this retrospective cohort study, all adult patients who underwent an NKB from April 1, 2013, to April 30, 2018, in a tertiary hospital were identified. The association between desmopressin use and bleeding complications, including hemoglobin fall, transfusion, hematoma, symptomatic hematoma, urgent radiologic study, and hypotension, was analyzed using multivariable logistic regression models. RESULTS: A total of 413 native kidney biopsies were studied, 79% of which were performed after receiving desmopressin. Patients receiving desmopressin had worse chronic kidney disease (eGFR 28 vs. 45 ml/min per 1.73 m2; P < 0.001) and were more often hospitalized (48% vs. 32%; P = 0.009). Despite higher bleeding risk, patients using desmopressin had a similar likelihood of symptomatic hematomas (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.13-1.14) and a lower need for urgent radiologic studies (OR, 0.33; 95% CI, 0.11-0.98). CONCLUSION: Patients at higher risk of bleeding using desmopressin before kidney biopsy had bleeding complications similar to those not using desmopressin. These results highlight potential important clinical and financial benefits of desmopressin use before kidney biopsy.
引用
- Leclerc S, Nadeau-Fredette AC, Elftouh N, et al. Use of Desmopressin Prior to Kidney Biopsy in Patients With High Bleeding Risk. Kidney Int Rep. 2020. PMID: 32775817. doi:10.1016/j.ekir.2020.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。